Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints

NCT06616571 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

336

Enrollment

INDUSTRY

Sponsor class

Conditions

Chemotherapy-Induced Febrile Neutropenia

Interventions

DRUG: QL0605(PEG-rhG-CSF)
DRUG: QL0605(PEG-rhG-CSF)

Sponsor

Qilu Pharmaceutical Co., Ltd.